- This article uses the International Nonproprietary Name "thiomersal", not the common U.S. spelling "thimerosal".
The thiomersal controversy describes claims that vaccines containing the mercury-based preservative thiomersal contribute to the development of autism and other brain development disorders. The current scientific consensus is that no convincing scientific evidence supports these claims, and a 2011 journal article described the vaccine-autism connection as "the most damaging medical hoax of the last 100 years".
Thiomersal is an organomercury compound used as a preservative in vaccines since the 1930s to prevent bacterial and fungal contamination. Following a mandated review of mercury-containing food and drugs, the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) asked vaccine makers to remove thiomersal from vaccines as quickly as possible as a purely precautionary measure, and it was rapidly phased out of most U.S. and European vaccines. In the context of perceived increased autism rates and increased number of vaccines in the childhood vaccination schedule, some parents believed the action to remove thiomersal was an indication that the preservative caused autism.
The potential impact of thiomersal on autism has been investigated extensively. Multiple lines of scientific evidence have shown that thiomersal does not cause autism. For example, the clinical symptoms of mercury poisoning differ significantly from those of autism. In addition, multiple population studies have found no association between thiomersal and autism, and rates of autism have continued to increase despite removal of thiomersal from vaccines. Thus, major scientific and medical bodies such as the Institute of Medicine and World Health Organization (WHO) as well as governmental agencies such as the Food and Drug Administration (FDA) and the CDC reject any role for thiomersal in autism or other neurodevelopmental disorders. In spite of the consensus of the scientific community, some parents and advocacy groups continue to contend that thiomersal is linked to autism.
This controversy has caused harm due to parents attempting to treat their autistic children with unproven and possibly dangerous treatments, discouraging parents from vaccinating their children due to fears about thiomersal toxicity and diverting resources away from research into more promising areas for the cause of autism. Thousands of lawsuits have been filed in the U.S. to seek damages from alleged toxicity from vaccines, including those purportedly caused by thiomersal. US courts have ruled against multiple representative test cases involving thiomersal, suggesting the majority are unlikely to succeed.
Thiomersal was introduced as a preservative in the 1930s to prevent the growth of infectious organisms such as bacteria and fungi, and has been in use in vaccines and other products such as immunoglobulin preparations and ophthalmic and nasal solutions. Vaccine manufacturers have used preservatives to prevent microbial growth during the manufacturing process or when packaged as "multi-dose" products to allow for multiple punctures of the same vial to dispense multiple vaccinations with less fear of contamination. After the FDA Modernization Act of 1997 mandated a review and risk assessment of all mercury-containing food and drugs, vaccine manufacturers responded to FDA requests made in December 1998 and April 1999 to provide detailed information about the thiomersal content of their preparations.
A review of the data showed that while the vaccine schedule for infants did not exceed FDA, Agency for Toxic Substances and Disease Registry (ATSDR), or WHO guidelines on mercury exposure, it could have exceeded Environmental Protection Agency (EPA) standards for the first six months of life, depending on the vaccine formulation and the weight of the infant. The review also highlighted difficulty interpreting toxicity of the ethylmercury in thiomersal because guidelines for mercury toxicity were based primarily on studies of methylmercury, a different mercury compound with different toxicologic properties. Multiple meetings were scheduled among various government officials and scientists from multiple agencies to discuss the appropriate response to this evidence. There was a wide range of opinions on the urgency and significance of the safety of thiomersal, with some toxicologists suggesting there was no clear evidence that thiomersal was harmful and other participants like Dr. Neal Halsey, director of the Institute of Vaccine Safety, strongly advocating removal of thiomersal from vaccines due to possible safety risks. In the process of forming the response to this information, the participants attempted to strike a balance between acknowledging possible harm from thiomersal and the actual risks involved if childhood vaccinations were delayed or stopped.
Upon conclusion of their review, the FDA, in conjunction with the other members of the US Public Health Service (USPHS), the National Institutes of Health (NIH), CDC and Health Resources and Services Administration (HRSA), in a joint statement with the AAP in July 1999 concluded that there was "no evidence of harm caused by doses of thimerosal found in vaccines, except for local hypersensitivity reactions."
Despite the lack of convincing evidence of toxicity of thiomersal when used as a vaccine preservative, the USPHS and AAP determined that thiomersal should be removed from vaccines as a purely precautionary measure. This action was based on the precautionary principle, which assumes that there is no harm in exercising caution even if it later turns out to be unnecessary. The CDC and AAP reasoned that despite the lack of evidence of significant harm in the use of thiomersal in vaccines, the removal of this preservative would increase the public confidence in the safety of vaccines. Although thiomersal was largely removed from routine infant vaccines by summer 2001 in the U.S., some vaccines continue to contain non-trace amounts of thiomersal, mainly in multi-dose vaccines targeted against influenza and tetanus.
In 2004 Quackwatch posted an article saying that chelation therapy has been falsely promoted as effective against autism, and that practitioners falsified diagnoses of metal poisoning to "trick" parents into having their children undergo the process. As of 2008[update], between 2–8% of children with autism had had the therapy.
Rationale for concern
Although intended to increase public confidence in vaccinations, the decision to remove thiomersal instead led to some parents suspecting thiomersal as a cause of autism. This concern over a vaccine-autism link grew from a confluence of several underlying factors. First, methylmercury had for decades been the subject of widespread environmental and media concern after two highly publicized episodes of poisonings in the 1950s and 1960s in Minamata Bay, Japan from industrial waste and in the 1970s in Iraq from fungicide contamination of wheat. These incidents led to new research on methylmercury safety and culminated in the publication of an array of confusing recommendations by public health agencies in the 1990s warning against methylmercury exposure in adults and pregnant women, which ensured a continued high public awareness of mercury toxicity. Second, the vaccine schedule for infants expanded in the 1990s to include more vaccines, some of which, including the Hib vaccine, DTaP vaccine and hepatitis B vaccine, could have contained thiomersal. Third, the number of diagnoses of autism grew in the 1990s, leading parents of these children to search for an explanation for the apparent rise in diagnoses, including considering possible environmental factors. The dramatic increase in reported cases of autism during the 1990s and early 2000s is largely attributable to changes in diagnostic practices, referral patterns, availability of services, age at diagnosis, and public awareness, and it is unknown whether autism's true prevalence increased during the period. Nevertheless, some parents believed that there was a growing "autism epidemic" and connected these three factors to conclude that the increase in number of vaccines, and specifically the mercury in thiomersal in those vaccines, were causing a dramatic increase in the incidence of autism.
Advocates of a thiomersal-autism link also relied on indirect evidence from the scientific literature, including analogy with neurotoxic effects of other mercury compounds, the reported epidemiologic association between autism and vaccine use, and extrapolation from in vitro experiments and animal studies Studies conducted by Mark Geier and his son David Geier have been the most frequently cited research by parents advocating a link between thiomersal and autism. This research by Geier has received considerable criticism for methodological problems in his research, including not presenting methods and statistical analyses to others for verification, improperly analyzing data taken from Vaccine Adverse Event Reporting System, as well as either mislabelling or confusing fundamental statistical terms in his papers, leading to results that were "uninterpretable".
Publicity of concern
Several months after the recommendation to have thiomersal removed from vaccines was published, a speculative article was published in Medical Hypotheses, a non-peer-reviewed journal, by parents who launched the parental advocacy group SafeMinds to promote the theory that thiomersal caused autism. The controversy began to gain legitimacy in the eyes of the public from this foundation, and gained widening support within certain elements in the autism advocacy community as well as in the political arena, with U.S. Representative Dan Burton openly supporting this movement and holding a number of Congressional hearings on the subject.
Further support for the association between autism and thiomersal appeared in an article by Robert F. Kennedy, Jr. in the magazines Rolling Stone and Salon.com alleging a government conspiracy at a CDC meeting to conceal the dangers of thiomersal to protect the pharmaceutical industry, and a book written by David Kirby, Evidence of Harm, dramatizing the lives of parents of autistic children, with both authors participating in media interviews to promote their work and the controversy. Although the allegations by Kennedy were denied and a US Senate committee investigation later found no evidence to substantiate the most serious allegations, the story had already been well publicized by leveraging Kennedy's celebrity. Salon magazine subsequently amended Kennedy's article five times due to factual errors and later retracted it completely on January 16, 2011, stating that the works of critics of the article and evidence of the flaws in the science connecting autism and vaccines undermined the value of the article to the editors.
Meanwhile, during this time of increased media publicity of the controversy, public health officials and institutions did little to rebut the concerns and speculative theories being offered. Media attention and polarization of the debate has also been fueled by personal injury lawyers who took out full-page ads in prominent newspapers and offered financial support for expert witnesses who dissented from the scientific consensus that there is no convincing evidence for a link between thiomersal and autism. Paul Offit, a leading vaccine researcher and advocate, has also noted a tendency in the media to provide false balance by perpetually presenting both sides of an issue even when only one side is supported by the evidence and thereby giving a platform for the spread of misinformation.
Despite the consensus from experts that there is no link between thiomersal and autism, many parents continue to hold on to their belief that such a link exists. These parents share the viewpoint that autism is not just treatable, but curable through "biomedical" interventions and have been frustrated by the lack of progress from more "mainline" scientists in finding this cure. Instead, they have supported an alternative community of like-minded parents, physicians and scientists who promote this belief. This mindset has taught these parents to challenge the expertise from the mainstream scientific community. Parents have also been influenced by a large number of online anti-vaccination websites that present themselves as an alternative source for evidence using pseudoscientific claims. These websites use emotional appeals to gather support and frame the controversy as an adversarial dispute between parents and a conspiracy of doctors and scientists. Advocates for a thiomersal-autism link have also relied on celebrities like model Jenny McCarthy and information presented on Don Imus' Imus in the Morning radio show to persuade the public to their cause, instead of relying only on "dry" scientific papers and scientists. McCarthy has published a book describing her personal experience with her autistic son and appeared on The Oprah Winfrey Show to promote the hypothesis of vaccines causing autism. Bitterness over this issue has led to numerous threats made against the CDC as well as researchers like Offit, with increased security placed by the CDC in response to these threats.
Various lines of evidence undermine a proposed link between thiomersal and autism. For example, although advocates of a thiomersal-autism link consider autism a form of "mercury poisoning," the typical symptoms of mercury toxicity are significantly different than symptoms seen in autism. Likewise, the neuroanatomic and histopathologic features of the brains of patients who have mercury poisoning, both with methylmercury as well as ethylmercury, have significant differences from the brains of people with autism. Previous episodes of widespread mercury toxicity in a population such as in Minamata Bay, Japan would also be expected to lead to documentation of a significant rise in autism or autism-like behavior in children should autism be caused by mercury poisoning. However, research on several episodes of acute and chronic mercury poisoning have not documented any such rise in autism like behavior. Although some parents cite an association between the timing of onset of autistic symptoms with the timing of vaccinations as evidence of an environmental cause such as thiomersal, this line of reasoning can be misleading. Associations such as these do not establish causation as the two occurring together may be only coincidental in nature. Also, genetic disorders that have no environmental triggers such as Rett syndrome and Huntington's disease nevertheless have specific ages when they begin to show symptoms, suggesting specific ages of onset of symptoms does not necessarily require an environmental cause.
Although the concern for a thiomersal-autism link was originally derived from indirect evidence based on the known potent neurotoxic effects of methylmercury, recent studies show these feared effects were likely overestimated. Ethylmercury, such as in thiomersal, clears much faster from the body after administration than methylmercury, suggesting total mercury exposure over time is much less with ethylmercury. Currently used methods of estimating brain deposition of mercury likely overestimates the amounts deposited due to ethylmercury, and ethylmercury also decomposes quicker in the brain than methylmercury, suggesting a lower risk of brain damage. These findings show that the assumptions that originally led to concern about the toxicity of ethylmercury, which were based on direct comparison to methylmercury, were flawed.
Multiple studies have been performed on data from large populations of children to study the relationship between the use of vaccines containing thiomersal, and autism and other neurodevelopmental disorders. Almost all of these studies have found no association between thiomersal-containing vaccines (TCVs) and autism, and studies done after the removal of thiomersal from vaccines have nevertheless shown autism rates continuing to increase. The only epidemiologic research that has found a purported link between TCVs and autism has been conducted by Mark Geier, whose flawed research has not been given any weight by independent reviews.
In Europe, a cohort study of 467,450 Danish children found no association between TCVs and autism or autism spectrum disorders (ASDs), nor any dose-response relationship between thiomersal and ASDs that would be suggestive of toxic exposure. An ecological analysis that studied 956 Danish children diagnosed with autism likewise did not show an association between autism and thiomersal. A retrospective cohort study on 109,863 children in the United Kingdom found no association between TCVs and autism, but a possible increased risk for tics. Analysis in this study also showed a possible protective effect with respect to general developmental disorders, attention-deficit disorder, and otherwise unspecified developmental delay. Another UK study based on a prospective cohort of 13,617 children likewise found more associated benefits than risks from thiomersal exposure with respect to developmental disorders. Because the Danish and UK studies involved only diphtheria-tetanus-pertussis (DTP) or diphtheria-tetanus (DT) vaccines, they are less relevant for the higher thiomersal exposure levels that occurred in the U.S.
In North America, a Canadian study of 27,749 children in Quebec showed that thiomersal was unrelated to the increasing trend in pervasive developmental disorders (PDDs). In fact, the study noted that rates of PDDs were higher in the birth cohorts with no thiomersal when compared to those with medium or high levels of exposure. A study performed in the US which analyzed data from 78,829 children enrolled in HMOs taken from the Vaccine Safety Datalink (VSD) did not show any consistent association between TCVs and neurodevelopmental outcomes, noting different results from data in different HMOs. Another study which studied children enrolled in HMOs that participated in the VSD found no evidence of a causal relationship between early exposure to mercury such as from thiomersal and deficits in neuropsychological functioning, although the authors did not address autism specifically. A later study performed in the same HMO groups found no increased risk of autism or autism spectrum disorders with increased exposure to thiomersal in early life from vaccines or immunoglobulins, and actually found decreased risk for ASDs with increased ethylmercury exposure when adjusting for covariates in certain exposure periods. A study performed in California found that removal of thiomersal from vaccines did not decrease the rates of autism, suggesting that thiomersal could not be the primary cause of autism. A study on children from Denmark, Sweden and California likewise argued against TCVs being causally associated with autism.
Due to growing concerns in the public, in 2001 the Centers for Disease Control and the National Institutes of Health asked the U.S. National Academy of Science's (NAS) Institute of Medicine to establish an independent expert committee to review hypotheses about existing and emerging immunization safety concerns. This initial report found that based on indirect and incomplete evidence available at the time, there was inadequate evidence to accept or reject a thiomersal-autism link, though it was biologically plausible.
Since this report was released, several independent reviews have examined the body of published research for a possible thiomersal-autism link by examining the theoretical mechanisms of thiomersal causing harm and by reviewing the in vitro, animal, and population studies that have been published. These reviews determined that no significant evidence exists to establish thiomersal as the cause of autism or other neurodevelopmental disorders.
The scientific consensus on the subject is reflected in a follow up report that was subsequently published in 2004 by the Institute of Medicine, which took into account new data that had been published since the 2001 report. The committee noted, in response to those who cite in vitro or animal models as evidence for the link between autism and thiomersal:
"However, the experiments showing effects of thimerosal on biochemical pathways in cell culture systems and showing abnormalities in the immune system or metal metabolism in people with autism are provocative; the autism research community should consider the appropriate composition of the autism research portfolio with some of these new findings in mind. However, these experiments do not provide evidence of a relationship between vaccines or thimerosal and autism. In the absence of experimental or human evidence that vaccination (either the MMR vaccine or the preservative thimerosal) affects metabolic, developmental, immune, or other physiological or molecular mechanisms that are causally related to the development of autism, the committee concludes that the hypotheses generated to date are theoretical only."
The committee concludes:
"Thus, based on this body of evidence, the committee concludes that the evidence favors rejection of a causal relationship between thimerosal-containing vaccines and autism." [bold in original]
Further evidence of the scientific consensus includes the rejection of a causal link between thiomersal and autism by multiple national and international scientific and medical bodies including the American Medical Association, the American Academy of Pediatrics, the American College of Medical Toxicology, the Canadian Paediatric Society, the U.S. National Academy of Sciences, the Food and Drug Administration, Centers for Disease Control and Prevention, the World Health Organization, the Public Health Agency of Canada, and the European Medicines Agency.
A 2011 journal article reflects this point of view and described the vaccine-autism connection as "the most damaging medical hoax of the last 100 years".
The suggestion that thiomersal has contributed to autism and other neurodevelopmental disorders has had a number of effects. Public health officials believe fear driven by advocates of a thiomersal-autism link has caused parents to avoid vaccination or adopt "made up" vaccination schedules that expose their children to increased risk from preventable diseases such as measles and pertussis. Advocates of a thiomersal-autism link have also helped enact laws in six states (California, Delaware, Illinois, Missouri, New York and Washington) between 2004 and 2006 to limit the use of thiomersal given to pregnant women and children, although later attempts in 2009 in twelve other states failed to pass. These laws can be temporarily suspended, but vaccine advocates doubt their utility given the lack of evidence for danger with thiomersal in vaccines. Vaccine advocates are also concerned that passage of such laws help fuel a backlash against vaccination and contribute to doubts about the safety of vaccines that are unwarranted.
During the period of time of removal of thiomersal, the CDC and AAP asked doctors to delay the birth dose of hepatitis B vaccine in children not at risk for hepatitis. This decision, though following the precautionary principle, nevertheless sparked confusion, controversy and some harm. Approximately 10% of hospitals suspended the use of hepatitis B vaccine for all newborns, and one child born to a Michigan mother infected with hepatitis B virus died of it. Similarly, a study found that the number of hospitals who failed to properly vaccinate infants of hepatitis B seropositive mothers rose by over 6 times. This is a potential negative outcome given the high probability that infants who acquire hepatitis B infection at birth will develop the infection in a chronic form and possibly liver cancer.
The notion that thiomersal causes autism has led some parents to have their children treated with costly and potentially dangerous therapies such as chelation therapy, which is typically used to treat heavy metal poisoning, due to parental fears that autism is a form of "mercury poisoning". As many as 2 to 8% of autistic children in the U.S., numbering as many as several thousand children per year, receive mercury-chelating agents. Although critics of using chelation therapy as an autism treatment point to a lack of any evidence to support its use, hundreds of doctors prescribe these medications despite possible side effects including nutritional deficiencies as well as damage to the liver and kidney. The popularity of this therapy caused a "public health imperative" that led the U.S. National Institute of Mental Health (NIMH) to commission a study about chelation in autism by studying DMSA, a chelating agent used for lead poisoning, despite worries from critics that there would be no chance it would show positive results and it would be unlikely to convince parents to not use the therapy. Ultimately, the study was halted due to ethical concerns that there would be too much risk to children with autism who did not have toxic levels of mercury or lead due to a new animal study showing possible cognitive and emotional problems associated with DMSA. A 5-year-old autistic boy died from cardiac arrest immediately after receiving chelation therapy treatment using EDTA in 2005.
The notion has also diverted attention and resources away from efforts to determine the causes of autism. The 2004 Institute of Medicine report committee recommended that while it supported "targeted research that focuses on better understanding the disease of autism, from a public health perspective the committee does not consider a significant investment in studies of the theoretical vaccine-autism connection to be useful at this time." Alison Singer, a senior executive of Autism Speaks, resigned from the group in 2009 in a dispute over whether to fund more research on links between vaccination and autism, saying, "There isn't an unlimited pot of money, and every dollar spent looking where we know the answer isn't is one less dollar we have to spend where we might find new answers."
From 1988 until August 2010, 5,632 claims relating to autism were made to Office of Special Masters of the U.S. Court of Federal Claims (commonly known as the "Vaccine Court") which oversees vaccine injury claims, of which one case has received compensation, 738 cases have been dismissed with no compensations made, and with the remaining cases pending. In the one case which received compensation, the U.S. government agreed to pay for injury to a child that had a pre-existing mitochondrial disorder who developed autism-like symptoms after multiple vaccinations, some of which included thiomersal. Citing the inability to rule out a role of these vaccinations in exacerbating her underlying mitochondrial disorder as the rationale for payment, CDC officials cautioned against generalizing this one case to all autism-related vaccine cases as most patients with autism do not have a mitochondrial disorder. In February 2009, this court also ruled on three autism-related cases, each exploring different mechanisms that plaintiffs proposed linked thiomersal-containing vaccines with autism. Three judges independently found no evidence that vaccines caused autism and denied the plaintiffs compensation. Since these same mechanisms formed the basis for the vast majority of remaining autism-related vaccine injury cases, the chance for compensation in any of these cases has significantly decreased. In March 2010, the court ruled in three other test cases that thiomersal-containing vaccines do not cause autism.
- Burton D (2003). "Mercury in medicine report" (PDF). Congressional Record 149: E1011–30.
- Immunization Safety Review Committee, Board on Health Promotion and Disease Prevention, Institute of Medicine (2004). Immunization Safety Review: Vaccines and Autism. Washington, DC: The National Academies Press. ISBN 0-309-09237-X.
- Doja A, Roberts W (2006). "Immunizations and autism: a review of the literature". Can J Neurol Sci 33 (4): 341–6. PMID 17168158.
- Flaherty DK (October 2011). "The Vaccine-autism Connection: A Public Health Crisis Caused by Unethical Medical Practices and Fraudulent Science". Ann Pharmacother 45 (10): 1302–4. doi:10.1345/aph.1Q318. PMID 21917556.
- "Thimerosal in vaccines". Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. 2007-09-06. Retrieved 2007-10-01.
- Baker JP (2008). "Mercury, Vaccines, and Autism: One Controversy, Three Histories". Am J Public Health 98 (2): 244–53. doi:10.2105/AJPH.2007.113159. PMC 2376879. PMID 18172138.
- "Thimerosal in vaccines: frequently asked questions (FAQs)". Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. 2007-06-07. Retrieved 2008-07-22.
- Nelson KB, Bauman ML (2003). "Thimerosal and autism?". Pediatrics 111 (3): 674–9. doi:10.1542/peds.111.3.674. PMID 12612255.
- World Health Organization (2006). "Thiomersal and vaccines: questions and answers". Retrieved 2009-05-19.
- Centers for Disease Control (2008-02-08). "Mercury and vaccines (thimerosal)". Retrieved 2011-08-01.
- Sugarman SD (2007). "Cases in vaccine court—legal battles over vaccines and autism". N Engl J Med 357 (13): 1275–7. doi:10.1056/NEJMp078168. PMID 17898095.
- Harris G, O'Connor A (2005-06-25). "On Autism's Cause, it's Parents vs. Research". New York Times. Retrieved 2010-07-02.
- Luscombe R (2009-01-25). "Charity chief quits over autism row". Observer (London). Retrieved 2009-02-01.
- Maugh TH II, Zajac A (2010-03-13). "'Vaccines court' rejects mercury–autism link in 3 test cases". Los Angeles Times.
- Vedantam, S (2009-02-13). "U.S. Court Finds No Link Between Vaccines, Autism". Washington Post. Retrieved 2009-08-22.
- American Academy of Pediatrics (1999-09-01). "Joint Statement of the American Academy of Pediatrics and the US Public Health Service (USPHS)". Retrieved 2007-07-22.
- Ball LK, Ball R, Pratt RD (2001). "An assessment of thimerosal use in childhood vaccines". Pediatrics 107 (5): 1147–54. doi:10.1542/peds.107.5.1147. PMID 11331700.
- Freed GL, Andreae MC, Cowan AE, Katz SL (June 2002). "The Process of Public Policy Formulation: The Case of Thimerosal in Vaccines". Pediatrics 109 (6): 1153–9. doi:10.1542/peds.109.6.1153. PMID 12042557.
- Offit PA (2007). "Thimerosal and vaccines—a cautionary tale". N Engl J Med 357 (13): 1278–9. doi:10.1056/NEJMp078187. PMID 17898096.
- "Thimerosal content in some US licensed vaccines". Institute for Vaccine Safety. 2009-10-21. Retrieved 2009-10-27.
- "Why Chelation Therapy Should Be Avoided". Quackwatch. 15 May 2004. Retrieved 7 October 2013.
- Stokstad E (2008). "Stalled trial for autism highlights dilemma of alternative treatments". Science 321 (5887): 326. doi:10.1126/science.321.5887.326. PMID 18635766.
- Szpir M (2006). "Tracing the Origins of Autism: A Spectrum of New Studies". Environ Health Perspect 114 (7): A412–8. doi:10.1289/ehp.114-a412. PMC 1513312. PMID 16835042.
- Rutter M (2005). "Incidence of autism spectrum disorders: changes over time and their meaning". Acta Paediatr 94 (1): 2–15. doi:10.1111/j.1651-2227.2005.tb01779.x. PMID 15858952.
- DeStefano F (2007). "Vaccines and Autism: Evidence Does Not Support a Causal Association". Clin Pharmacol Ther 82 (6): 756–9. doi:10.1038/sj.clpt.6100407. PMID 17928818.
- Allen A (2007-05-28). "Thiomersal on Trial: The Theory that Vaccines Cause Autism goes to Court". Slate. Retrieved 2008-01-30.
- Parker SK, Schwartz B, Todd J, Pickering LK (2004). "Thimerosal-containing Vaccines and Autistic Spectrum Disorder: A Critical Review of Published Original Data". Pediatrics 114 (3): 793–804. doi:10.1542/peds.2004-0434. PMID 15342856.Parker, S; Todd, J, Schwartz, B, Pickering, L (2005 Jan). "Erratum: Thimerosal-containing Caccines and Autistic Spectrum Disorder: A Critical Review of Published Original Data". Pediatrics 115 (1): 200. doi:10.1542/peds.2004-2402. PMID 15630018.
- Bernard S, Enayati A, Redwood L, Roger H, Binstock T (2001). "Autism: a novel form of mercury poisoning". Med Hypotheses 56 (4): 462–71. doi:10.1054/mehy.2000.1281. PMID 11339848.
- Gross L (2009). "A Broken Trust: Lessons from the Vaccine–Autism Wars". PLoS Biol 7 (5): 756–9. doi:10.1371/journal.pbio.1000114. PMC 2682483. PMID 19478850.
- R. F. Kennedy, Jr. (June 20, 2005). "Deadly Immunity (corrected)". Salon, Rolling Stone. Archived from the original on 2009-05-14. Retrieved 2009-05-14.
- Verstraeten T (April 2004). "Thimerosal, the Centers for Disease Control and Prevention, and GlaxoSmithKline". Pediatrics 113 (4): 932. doi:10.1542/peds.113.4.932. ISSN 1098-4275. OCLC 38589589. PMID 15060252. Retrieved 2009-05-14.
- Enzi MB (September 2007 Salo). "Enzi Says Investigation Does Not Support Allegations of Misconduct in Autism Research" (PDF). U.S. Senate Committee on Health, Education, Labor and Pensions. Retrieved 2010-06-22.
- Kerry Lauerman (16 January 2011). "Correcting our record". Salon.com. Retrieved 2011-01-16. "At the time, we felt that correcting the piece—and keeping it on the site, in the spirit of transparency—was the best way to operate. But subsequent critics [...] further eroded any faith we had in the story's value. We've grown to believe the best reader service is to delete the piece entirely."
- Laura Helmuth (11 June 2013). "So Robert F. Kennedy Jr. Called Us to Complain …". Salon.com. Retrieved 2013-06-12. "Robert F. Kennedy Jr.'s elaborate conspiracy theory is [...] delusional and dangerous."
- Begley, Sharon (21 February 2009). "Anatomy of a Scare". Newsweek. Retrieved 20 September 2010.
- Aschner M, Ceccatelli S (2010). "Are Neuropathological Conditions Relevant to Ethylmercury Exposure?". Neurotox Res 18 (1): 59–68. doi:10.1007/s12640-009-9113-2. PMID 19756911.
- Hviid A, Stellfeld M, Wohlfahrt J, Melbye M (2003). "Association between Thimerosal-containing Vaccine and Autism". JAMA 290 (13): 1763–6. doi:10.1001/jama.290.13.1763. PMID 14519711.
- Madsen KM, Lauritsen MB, Pedersen CB et al. (2004). "Thimerosal and the Occurrence of Autism: Negative Ecological Evidence from Danish Population-based Data". Pediatrics 112 (3): 604–6. doi:10.1542/peds.112.3.604. PMID 12949291.
- Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B (2004). "Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United kingdom Does Not Support a Causal Association". Pediatrics 114 (3): 584–91. doi:10.1542/peds.2003-1177-L. PMID 15342825.
- Heron J, Golding J, ALSPAC Study Team (2004). "Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association". Pediatrics 114 (3): 577–83. doi:10.1542/peds.2003-1176-L. PMID 15342824.
- Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D (2006). "Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations". Pediatrics 118 (1): e139–50. doi:10.1542/peds.2005-2993. PMID 16818529.
- Verstraeten T, Davis RL, DeStefano F et al. (2003). "Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases". Pediatrics 112 (5): 1039–48. doi:10.1542/peds.112.2.e98. PMID 14595043.
- Thompson WW, Price C, Goodson B et al. (2007). "Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years". N Engl J Med 357 (13): 1281–92. doi:10.1056/NEJMoa071434. PMID 17898097. Lay summary – NNii (2007).
- Price CS, Thompson WW, Goodson B, et al. (October 2010). "Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism". Pediatrics 126 (4): 656–64. doi:10.1542/peds.2010-0309. PMID 20837594.
- Schechter R, Grether JK (2008). "Continuing increases in autism reported to California's developmental services system: mercury in retrograde". Arch Gen Psychiatry 65 (1): 19–24. doi:10.1001/archgenpsychiatry.2007.1. PMID 18180424. Lay summary – Associated Press (2008-01-07).
- Stehr-Green P, Bettles J, Robertson LD (March 2002). "Autism and thimerosal-containing vaccines: Lack of consistent evidence for an association". Am J Prev Med 92 (3): 443–4. doi:10.1016/S0749-3797(03)00113-2. PMC 1447096. PMID 11867327.
- Immunization Safety Review Committee, Board on Health Promotion and Disease Prevention, Institute of Medicine (2001). Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders. Washington, DC: National Academy Press. ISBN 0-309-09008-3.
- Parker SK, Schwartz B, Todd J, Pickering LK (2004). "Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data". Pediatrics 114 (3): 793–804. doi:10.1542/peds.2004-0434. PMID 15342856.
- Parker S, Todd J, Schwartz B, Pickering L (January 2005). "Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data". Pediatrics 115 (1): 200. doi:10.1542/peds.2004-2402. PMID 15630018. Retrieved 2012-03-24.
- American Medical Association (2004-05-18). "AMA Welcomes New IOM Report Rejecting Link Between Vaccines and Autism". Retrieved 2007-07-23.
- American Academy of Pediatrics (2004-05-18). "What Parents Should Know About Thimerosal". Retrieved 2007-07-23.
- Kurt TL (2006). "ACMT position statement: the Iom report on thimerosal and autism" (PDF). J Med Toxicol 2 (4): 170–1. doi:10.1007/BF03161188. PMID 18072140.
- Infectious Diseases and Immunization Committee, Canadian Paediatric Society (2007). "Autistic spectrum disorder: No causal relationship with vaccines". Paediatr Child Health 12 (5): 393–5. Retrieved 2008-10-17. Also published (2007) in Can J Infect Dis Med Microbiol 18 (3): 177–9. PMID 18923720.
- National Advisory Committee on Immunization (2007). "Thimerosal: updated statement. An Advisory Committee Statement". Can Commun Dis Rep 33 (ACS–6): 1–13. PMID 17663033.
- European Medicines Agency (2004-03-24). "EMEA Public Statement on Thiomersal in Vaccines for Human Use". Retrieved 2007-07-22.
- Schubert C (January 2010). "Pandemic blows lid off laws limiting mercury in vaccines". Nat. Med. 16 (1): 9. doi:10.1038/nm0110-9a. PMID 20057400.
- Stokstad E (2008). "Stalled Trial for Autism Highlights Dilemma of Alternative Treatments". Science 321 (5887): 326. doi:10.1126/science.321.5887.326. PMID 18635766.
- USAToday.com (2005-08-25). "Autistic boy dies after unproven treatment". USA Today. Retrieved 2009-08-22.
- "National Vaccine Injury Compensation Program statistics reports". Health Resources and Services Administration. 2008-01-08. Retrieved 2008-01-22.
- Stobbe M, Marchione M (2008-03-07). "Analysis: vaccine-autism link unproven". Associated Press. Retrieved 2008-06-06.
- Honey K (2008). "Attention focuses on autism". J Clin Invest 118 (5): 1586–7. doi:10.1172/JCI35821. PMC 2336894. PMID 18451989.